
Banner Messages for the 01-24-22 and 01-28-2022 Reports

This file contains abbreviated messages meant to provide timely notifications that affect all provider groups (physicians, dentists, and so forth). Additional current and historic information affecting the Medicaid, Medicaid Managed Care, and Children with Special Health Care Needs (CSHCN) Services Program provider community may be found in the earlier postings of these files in the TMHP banner library at www.tmhp.com.

Copyright Acknowledgments

Use of the AMA's copyrighted CPT® is allowed in this publication with the following disclosure:

“Current Procedural Terminology (CPT) is copyright 2021 American Medical Association. All rights reserved. No fee schedules, basic units, relative values, or related listings are included in CPT. The AMA assumes no other health insurance liability for the data contained herein. Applicable Federal Acquisition Regulation System/Defense Federal Acquisition Regulation Supplement (FARS/DFARS) apply.”

The American Dental Association requires the following copyright notice in all publications containing Current Dental Terminology (CDT) codes:

“*Current Dental Terminology* (including procedure codes, nomenclature, descriptors, and other data contained therein) is copyright © 2021 American Dental Association. All Rights Reserved. Applicable FARS/DFARS apply.”

Microsoft Corporation requires the following notice in publications containing trademarked product names:

“Microsoft® and Windows® are either registered trademarks or trademarks of Microsoft Corporation in the United States and/or other countries.”

Total Messages (26)

1 (01/14/22 through 02/04/22) ***Attention All Providers*******

On December 23, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Merck oral COVID-19 drug Molnupiravir for the treatment of mild to moderate COVID-19 in adults 18 or older.

Details are available on the TMHP website at www.tmhp.com. [\[link\]](#)

For more information, call the TMHP Contact Center at 800-925-9126 or the TMHP-CSHCN Services Program Contact Center at 800-568-2413.

2 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

The Texas Health and Human Services Commission (HHSC) will include COVID-19 at-home test kits as a Medicaid, Children's Health Insurance Program (CHIP), Healthy Texas Women (HTW), Kidney Health Care (KHC), and Children with Special Health Care Needs (CSHCN) pharmacy benefit beginning January 3, 2022, for fee-for-service (FFS) and no later than January 17, 2022, for managed care.

Details are available on the TMHP website at www.tmhp.com. [\[link\]](#)

For more information, call the TMHP Contact Center at 800-925-9126.

3 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

On December 22, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Pfizer oral COVID-19 drug Paxlovid. The medication treats mild to moderate COVID-19 in adults and children 12 years of age or older who are at high risk for progression to severe COVID-19.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

4 (01/07/22 through 01/28/22) ***Attention All Medicaid Providers*******

On December 9, 2021, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to approve a booster dose for persons 16 and 17 years of age. Additionally, starting December 13, 2021, Pfizer is expected to begin distributing a new formulation of the multiple-dose Pfizer-BioNTech COVID-19 vaccine that does not require dilution.

The Texas Health and Human Services Commission (HHSC) is updating pharmacy benefit coverage for the Pfizer-BioNTech COVID-19 vaccine.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

5 (01/21/22 through 02/11/22) ***Attention All Medicaid Providers*******

The Texas Health and Human Services Commission (HHSC) has become aware of a drug shortage of Vibramycin 25mg/5mL suspension in the tetracycline drug class because of Pfizer's discontinuation of the product. HHSC has received reports of a shortage from managed care organizations (MCOs) and verified it on the U.S. Food and Drug Administration drug shortage website.

In response to the shortage of the preferred brand product Vibramycin 25mg/5mL suspension, national drug code (NDC) 0069-0971-95, HHSC has temporarily removed the non-preferred status from the generic product, doxycycline 25mg/5mL suspension, on the preferred drug list (PDL).

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

6 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

There is a document that has been updated with instructions on how to complete Healthy Texas Women (HTW) certifications and attestations using the Provider Enrollment and Management System (PEMS).

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

7 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

On January 13, 2022, TMHP added the new Electronic Visit Verification (EVV) Consumer Directed Services (CDS) Employer Usage Report to the EVV Portal and updated the TMHP Learning Management System (LMS) to include the new report.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, email evv@tmhp.com.

8 (01/21/22 through 02/11/22) ***Attention All Medicaid Providers*******

On January 3, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

9 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

Effective for dates of service on or after January 1, 2022, the reimbursement rates for some drugs' procedure codes have been implemented for Texas Medicaid.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

10 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

Effective for dates of service on or after December 9, 2021, in accordance with the U.S. Food and Drug Administration's (FDA) amended emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, COVID-19 vaccine administration code 0004A (the booster dose of the Pfizer-BioNTech COVID-19 vaccine) is now a benefit of Medicaid, Healthy Texas Women (HTW), the Family Planning Program (FPP), and the Children with Special Health Care Needs (CSHCN) Services Program for clients 16 or 17 years old.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

11 (01/21/22 through 02/11/22) ***Attention All Medicaid Providers*******

Effective for dates of service on or after March 1, 2022, pneumococcal vaccine procedure codes 90671 and 90677 will become benefits of Texas Medicaid for clients who are 18 years of age or older.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

12 (01/21/22 through 02/11/22) ***Attention All Medicaid Providers*******

Beginning March 1, 2022, prior authorization criteria will be effective for hypoglossal nerve stimulator (HNS) procedure code 64582 in Texas Medicaid.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

13 (01/21/22 through 02/11/22) ***Attention All Medicaid Providers*******

Effective for dates of service on or after March 1, 2022, prior authorization will be required for laser interstitial thermal therapy procedure codes 61736 and 61737 in Texas Medicaid.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

14 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

Effective for dates of service on or after March 1, 2022, benefit criteria will change for intravenous (IV) therapy equipment and supplies in Texas Medicaid.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

15 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

Effective for dates of service on or after March 1, 2022, renal dialysis benefits will change for Texas Medicaid.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

16 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

Effective for dates of service on or after March 1, 2022, benefit criteria will be added for vestibular evoked myogenic potentials (VEMP) procedure codes 92517, 92518, and 92519.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126.

17 (01/14/22 through 02/04/22) ***Attention All Medicaid Providers*******

Effective for dates of service on or after March 1, 2022, wound care equipment and supplies procedure code A4247 will be limited to one box per month.

For more information, call the TMHP Contact Center at 800-925-9126. [[link](#)]

18 (01/07/22 through 01/28/22) ***Attention All Medicaid and CSHCN Services Program Providers*******

The enrollment application fee for institutional providers for the calendar year 2022 has increased to \$631.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126 or the TMHP-CSHCN Services Program Contact Center at 800-568-2413.

19 (01/14/22 through 02/04/22) ***Attention All Medicaid and CSHCN Services Program Providers*******

Provider enrollment functions are available through the Provider Enrollment and Management System (PEMS), and there are two ways to enroll performing providers in PEMS.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126 or the TMHP-CSHCN Services Program Contact Center at 800-568-2413.

20 (01/14/22 through 02/04/22) ***Attention All Medicaid and CSHCN Services Program Providers*******

Texas Medicaid & Healthcare Partnership (TMHP) is experiencing an unusually high volume of calls from providers with questions about the Provider Enrollment and Management System (PEMS).

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126 or the TMHP-CSHCN Services Program Contact Center at 800-568-2413.

21 (01/21/22 through 02/11/22) ***Attention All Medicaid and CSHCN Services Program Providers*******

Effective for dates of service on or after March 1, 2022, wound care management procedure codes Q4173 and Q4174 will become benefits for Texas Medicaid and the Children with Special Health Care Needs (CSHCN) Services Program clients. Wound care management procedure codes Q4115 and Q4132 will no longer be benefits effective March 1, 2022.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126 or the TMHP-CSHCN Services Program Contact Center at 800-568-2413.

22 (01/14/22 through 02/04/22) ***Attention All Medicaid and CSHCN Services Program Providers*******

The Texas Medicaid & Healthcare Partnership (TMHP) has recently implemented a new Provider Enrollment and Management System (PEMS), effective December 13, 2021. Because of the transition to the new enrollment system, all existing applications in the former enrollment system, Provider Enrollment on the Portal (PEP), must be completed by February 15, 2022.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP Contact Center at 800-925-9126 or the TMHP-CSHCN Services Program Contact Center at 800-568-2413.

23 (01/21/22 through 02/11/22) ***Attention All CSHCN Services Program Providers*******

Beginning March 1, 2022, prior authorization criteria will be in effect for hypoglossal nerve stimulator (HNS) procedure code 64582.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

24 (01/21/22 through 02/11/22) ***Attention All CSHCN Services Program Providers*******

Beginning March 1, 2022, prior authorization criteria will be in effect for hypoglossal nerve stimulator (HNS) procedure code 64582.

Details are available on the TMHP website at www.tmhp.com. [[link](#)]

For more information, call the TMHP-CSHCN Services Program Contact Center at 800-568-2413.

25 (01/07/22 through 01/28/22) ***Attention All CSHCN Services Program Providers*******

Effective for dates of service on or after January 1, 2022, limited orthodontic treatment procedure codes D8010 and D8020 will be benefits in the Children with Special Health Care Needs (CSHCN) Services Program.

Details are available on the Texas Medicaid & Healthcare Partnership (TMHP) website at www.tmhp.com.
[\[link\]](#)

For more information, call the TMHP-CSHCN Services Program Contact Center at 800-568-2413.

26 (01/14/22 through 02/04/22) ***Attention Behavioral Health Providers*******

As required by Senate Bill (SB) 640 (87th Legislature, 2021, Regular Session), the Texas Health and Human Services Commission (HHSC), in collaboration with behavioral health stakeholders, is conducting a survey to better understand the opportunities and barriers to sharing clinical data with other health-care providers. Additional information and the survey link are forthcoming.

Details are available on the TMHP website at www.tmhp.com. [\[link\]](#)